TABLE 6.

Clinical trials and clinical applications of experimental approaches to increase ABCC1 expression.

Experimental approach	Clinical trials and applications
St. John’s wort	See Table 5
Thiethylperazinea	AD (NCT03417986)

^aNCT03417986 was a phase 2 trial investigating safety and efficacy of thiethylperazine in subjects with early onset AD. The status of the trial is listed on ClinicalTrials.gov as “Completed” (Actual Study Completion Date: October 22, 2021). The results of the trial have apparently not been published; no results were found with a PubMed search of “Thiethylperazine and Alzheimer’s.”

Clinical trials are identified by ClinicalTrials.gov identifier (NCT number). ABCCA1, ATP binding cassette subfamily C member 1; AD, Alzheimer’s disease.